Navigation Links
Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2
Date:7/29/2008

for targeting neurological and psychiatric diseases."

Dr. Ross is a leader in neurodegenerative disease research; he helped to define LRRK2 as a PD target, and is an expert in its biology. As part of the collaboration, Zenobia will have access to cell assays and animal models developed by the Ross laboratory. "We are very excited to combine our expertise in fragment-based lead discovery with the expertise of Dr. Ross," said Vicki Nienaber, Ph.D., President and Founder of Zenobia. "We are a long way from a cure, but we took the first step this week with the help of the Michael J. Fox foundation."

Zenobia's research is focused on debilitating, limited-population diseases that have no cure. Zenobia combines fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for illnesses such as Parkinson's disease, Huntington's disease and Muscular Dystrophy. In the future, Zenobia will focus on psychiatric diseases in parallel with increased understanding of the biology of these diseases.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at vicki@zenobiatherapeutics.com or visit http://www.zenobiatherapeutics.com.


'/>"/>
SOURCE Zenobia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
3. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
4. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
5. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
6. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
7. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
8. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
11. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... December 23, 2014 Pipette.com announces their ... Twitter followers can submit their #HolidayInTheLab pictures for a ... lab mates. , For those struggling to think of ... Pipette.com Holiday in the Lab Contest provides the ideal ... followers to send pictures of their chemistree, holiday ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3
... (Nasdaq and SWX: BMRN) announced today the appointment,of ... Former Vice President of,Research and Development for Raven ... patents and the recipient of a,collection of prestigious ... Awards from Intellectual Property Owners, Inc., "We ...
... Therapeutics Inc., an,early stage biotechnology company developing therapies ... Drug application (IND),to the U.S. Food and Drug ... the first-in-man clinical trials for its lead compound,VEL-0230., ... has dual-acting properties, in,that it both stimulates bone ...
... N.J., Jan. 28 Ferring Pharmaceuticals Inc.,has announced ... will serve as the title sponsor of the ... GeezerJock of the Year,Award., "This is such ... for,senior athletes," said Alex Drigan, Product Manager, EUFLEXXA(TM). ...
Cached Biology Technology:BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 2BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 3Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Rehabilitation Medicine at NYU Langone Medical Center will ... rehabilitation, the treatment of traumatic brain injuries and ... at the American Association of Physical Medicine and ... 2011. Experts will be available to comment about ...
... (University of Turku and VTT Technical Research Centre of Finland) ... Institute for Health and Welfare) have discovered that the SHARPIN ... leading journal, the study concludes that SHARPIN regulates the movement ... cancer cells. It is likely that the discovery will also ...
... Palo Alto, CAU.S. scientists have developed a new, integrated, ... carbon cycle and people,s role in it. Understanding the carbon ... sustainable future. The plan builds on the first such plan, ... the role of humans as agents and managers of carbon ...
Cached Biology News:Rusk experts present at American Association of Physical Medicine and Rehabilitation meeting 2Scientists tackle the carbon conundrum 2
... low melting point agarose used for second-dimension ... in place for most applications. Bromophenol Blue ... of electrophoresis runs. The solution is composed ... 1x Tris, glycine, SDS, and 0.003% Bromophenol ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... IEF cell is an apparatus dedicated to ... or agarose slab gels. The cell includes ... casting tray, 5 glass plates, 50 sheets ... sample templates, and instructions. Dimensions are 21 ...
... The Biomek FXP is the latest entry ... for greater positional accuracy and increased robustness, it ... application. It can be configured with either one ... capacity, the Biomek FXP sets the standard for ...
Biology Products: